Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | Chief Business Officer | June 01, 2025 | June 03, 2025 |
| NEUROONE MEDICAL TECHNOLOGIES CorpNMTC · Entity 7808 | Chief Business Officer | August 27, 2026 | September 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date June 01, 2025 · Filed June 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2035-05-31 | Direct | 250,000 |
Reported balance
After 2025-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-01 · Grant · Acquired 250,000 · Balance 250,000 F1: Vests with respect to 25% of the underlying common shares on June 1, 2026 with the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2026. |
| Voting Common Shares, no par value per shareSEC Table I · non-derivative | Direct | 527,114 |
Reported balance
Holding disclosure · report date 2025-06-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 527,114 |
Filing footnotes · ownership attribution and instrument terms
F1: Vests with respect to 25% of the underlying common shares on June 1, 2026 with the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2026.
NEUROONE MEDICAL TECHNOLOGIES Corp
Report date August 27, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 199,999 |
Reported balance
After 2026-08-27 transaction · row 1
1 source rowRow 1 · 2026-08-27 · Purchase · Acquired 33,333 · Balance 199,999 F1: The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $2.00 and $2.017 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2036-08-27 | Direct | 35,000 |
Reported balance
After 2026-08-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-28 · Grant · Acquired 35,000 · Balance 35,000 F2: 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $2.00 and $2.017 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.
F2: 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2026 Filed Sep 8, 2026 12:31 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 35,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001971798-26-000005 · primary_doc.xml · derivative · entry 2 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-08-27 F2 · derivative.exercise_date: 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments. Read SEC document |
| August 27, 2026 Filed Sep 8, 2026 12:31 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | PurchaseCommon Stock | 33,333 | $2.01 | $66,999.33 |
DisclosureSEC source: 0001971798-26-000005 · primary_doc.xml · nonDerivative · entry 1 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,999 F1 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $2.00 and $2.017 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 13:49 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 500,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001971798-26-000002 · primary_doc.xml · derivative · entry 2 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2036-02-29 F1 · derivative.exercise_date: 25% will vest on March 1, 2027, and the remaining 75% will vest in 12 equal installments on the last day of each quarter beginning on March 31, 2027. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 13:49 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | PurchaseCommon Stock | 1,000,000 | $0.67 | $670,400.00 |
DisclosureSEC source: 0001971798-26-000002 · primary_doc.xml · nonDerivative · entry 1 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:19 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001437749-25-019296 · rdgdoc.xml · derivative · entry 2 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Shares · 250,000 shares Expires 2035-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2026 with the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2026. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 21:06 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000053 · primary_doc.xml · derivative · entry 2 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Shares · 130,000 shares Expires 2034-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2025. Read SEC document |
| November 16, 2023 Filed Nov 16, 2023 21:37 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 20,000 | $2.46 | $49,200.00 |
DisclosureSEC source: 0001235802-23-000111 · primary_doc.xml · nonDerivative · entry 1 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,114 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.42 to $2.49, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:14 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 38,364 | $3.91 | $150,003.24 |
DisclosureSEC source: 0001235802-23-000069 · primary_doc.xml · nonDerivative · entry 1 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 507,114 Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:40 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001235802-23-000040 · primary_doc.xml · derivative · entry 2 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Shares · 140,000 shares Expires 2033-04-09 F1 · derivative.exercise_date: This option vests with respect to 35,000 common shares on April 10, 2024 and with respect to the remaining 75% of the common shares in 12 as nearly equal as possible quarterly installments commencing three months after the one-year anniversary of the grant date. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:40 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 468,750 | $1.60 | $750,000.00 |
DisclosureSEC source: 0001235802-23-000040 · primary_doc.xml · nonDerivative · entry 1 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,750 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.